For example, even with a state-of-the-art digital PET/CT and at high PSA values at recurrence, up to 5% of prostate cancers do not express sufficient the prostate specific membrane antigen (PSMA) to be usefully imaged by this technique [15]. This evidence concerns the gene FOLH1 and prostate carcinoma.